|
IIeocolitis
|
0.300 |
Biomarker
|
disease |
CTD_human |
TLR2, TLR4 and TLR9 polymorphisms and Crohn's disease in a New Zealand Caucasian cohort.
|
17914947 |
2007 |
|
Crohn's disease of large bowel
|
0.300 |
Biomarker
|
disease |
CTD_human |
Crohn's disease is associated with a toll-like receptor-9 polymorphism.
|
15236225 |
2004 |
|
Crohn's disease of the ileum
|
0.300 |
Biomarker
|
disease |
CTD_human |
Crohn's disease is associated with a toll-like receptor-9 polymorphism.
|
15236225 |
2004 |
|
Regional enteritis
|
0.300 |
Biomarker
|
disease |
CTD_human |
Crohn's disease is associated with a toll-like receptor-9 polymorphism.
|
15236225 |
2004 |
|
IIeocolitis
|
0.300 |
Biomarker
|
disease |
CTD_human |
Crohn's disease is associated with a toll-like receptor-9 polymorphism.
|
15236225 |
2004 |
|
Necrotizing Enterocolitis
|
0.210 |
Biomarker
|
disease |
BEFREE |
Reciprocal expression and signaling of TLR4 and TLR9 in the pathogenesis and treatment of necrotizing enterocolitis.
|
19109197 |
2009 |
|
Necrotizing Enterocolitis
|
0.210 |
Biomarker
|
disease |
RGD |
Changes in intestinal Toll-like receptors and cytokines precede histological injury in a rat model of necrotizing enterocolitis.
|
19608731 |
2009 |
|
Pancreatitis, Acute Necrotizing
|
0.200 |
Biomarker
|
disease |
RGD |
Toll-like receptor 9 is expressed in rat pancreas and is involved in cerulein-induced pancreatitis.
|
18376319 |
2008 |
|
Neuritis, Autoimmune, Experimental
|
0.200 |
Biomarker
|
disease |
RGD |
Expression of TLR4 and TLR9 mRNA in Lewis rats with experimental allergic neuritis.
|
18434754 |
2007 |
|
Anxiety
|
0.110 |
GeneticVariation
|
disease |
GWASCAT |
Meta-analysis of genome-wide association studies for neuroticism in 449,484 individuals identifies novel genetic loci and pathways.
|
29942085 |
2018 |
|
Anxiety
|
0.110 |
Biomarker
|
disease |
BEFREE |
Our findings demonstrate functional relevance of TLR9 in protecting stressed mammals from overreacting to traumatic experiences and suggest using oligonucleotide-mediated peripheral TLR9 activation to potentiate the innate immune system and prevent post-traumatic inflammation and anxiety.
|
22832815 |
2012 |
|
Autoimmune Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Recent findings demonstrated that Toll-like receptor 9 (TLR9) was involved in B cell tolerance breaking of autoimmune disease, including AAV.
|
31790283 |
2020 |
|
Malignant tumor of cervix
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Our findings suggest that the TLR9 1486 T/C and G2848A polymorphisms contribute to cervical cancer risk, but there is no association of the TLR2-196 to -174 del/ins polymorphism with cervical cancer.
|
30215163 |
2020 |
|
Neoplasm Metastasis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
TLR9 agonist or lactoferrin treatment can rescue this phenotype in the tumor metastasis mouse model.
|
31462711 |
2020 |
|
Septicemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
TLR9 in DCs mediated IL-17A production in γδT cells during sepsis and contributed to the development of septic AKI.
|
31760767 |
2020 |
|
Sepsis
|
0.100 |
Biomarker
|
disease |
BEFREE |
TLR9 in DCs mediated IL-17A production in γδT cells during sepsis and contributed to the development of septic AKI.
|
31760767 |
2020 |
|
Cervix carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Our findings suggest that the TLR9 1486 T/C and G2848A polymorphisms contribute to cervical cancer risk, but there is no association of the TLR2-196 to -174 del/ins polymorphism with cervical cancer.
|
30215163 |
2020 |
|
cervical cancer
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Our findings suggest that the TLR9 1486 T/C and G2848A polymorphisms contribute to cervical cancer risk, but there is no association of the TLR2-196 to -174 del/ins polymorphism with cervical cancer.
|
30215163 |
2020 |
|
Asthma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We show that TLR9 activation by CpG A suppresses IL-33-mediated AHR and airway inflammation through inhibition of ILC2s.
|
30914379 |
2019 |
|
Autoimmune Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Some AMPs are also strongly immunomodulatory: LL37-DNA complexes potently amplify Toll-like receptor 9 (TLR9) activation in immune cells and exacerbate autoimmune diseases.
|
30833557 |
2019 |
|
Autoimmune Diseases
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Induced expression of Toll-like receptor 9 in peritubular capillary endothelium correlates with the progression of tubulointerstitial lesions in autoimmune disease-prone mice.
|
30813872 |
2019 |
|
Autoimmune Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Finally, we discuss the implications of TLR9 subcellular localization in autoimmunity.
|
30900780 |
2019 |
|
Malignant neoplasm of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
The major research questions: (1) How does cell free rDNA content change in breast cancer; (2) What type of response in the MCF7 breast cancer cells is caused by cf-rDNA; and (3) What type of DNA sensors (TLR9 or AIM2) is stimulated in MCF7 in response to the action of cf-rDNA?
|
31205871 |
2019 |
|
Malignant neoplasm of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
Oligodeoxynucleotides ODN 2006 and M362 Exert Potent Adjuvant Effect through TLR-9/-6 Synergy to Exaggerate Mammaglobin-A Peptide Specific Cytotoxic CD8+T Lymphocyte Responses against Breast Cancer Cells.
|
31091800 |
2019 |
|
Malignant Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Recently, changing expression levels of TLR9 has been observed in a wide range of cancer
|
31450898 |
2019 |